Evaluating only Magenta Therapeutics’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Market collapse.
Magenta Therapeutics raised 350 million dollars to develop less toxic conditioning regimens for bone marrow transplants, replacing chemotherapy with targeted agents. After multiple pipeline failures in clinical development, the company dissolved in January 2023 and returned remaining capital to shareholders.
Lesson
“Bone marrow transplant conditioning is one of the most difficult therapeutic areas to disrupt because the bar for safety and efficacy against standard chemotherapy is extremely high.”